General Discussions, page-81

Hard to compare. NYR a long way behind at this stage, from the announcement it looks like they'll try to start phase 1 later this year, whereas AGN is starting phase 2 right now. There isn't much information in their announcement that allows for comparison, however all we were given is that NYR's drug reduced penumbra (the area of brain that is 'under threat' but not dead yet) in the rats by 42%. In AGN's pre-clinical studies the effect has been a reduction of around 65% of total infarct volume, replicated across multiple studies in both rats and primates. If NYR gave us how much it reduced total infarct volume a comparison could be made. A big pro for AGN is that ARG-007 is a once off infusion, whereas NYR's drug is given as a continuous infusion over 72 hours! Much less practical.